Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity
PHARMACEUTICAL CHEMISTRY JOURNAL(2022)
Abstract
The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2- a ]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%. No evidence of drug accumulation from an RU-891 270-mg tablet dosage form was detected in rabbits upon threefold administration at a dose of 23 mg/kg.
MoreTranslated text
Key words
bioavailability,9-dihydrophenacyl dihydroimidazobenzimidazole,HPLC
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined